Continuous-Flow LVAD Patient Outcomes: 27 Cases with 5.4-Month Median Follow-Up

Qiuju Ding's retrospective study analyzes perioperative profiles and longitudinal outcomes for 27 patients with end-stage heart failure supported by continuous-flow left ventricular assist devices (CF-LVADs). The data covers patients implanted between October 2022 and July 2025, with a median follow-up of 5.4 months. It includes clinical characteristics, survival, readmission rates, and changes in cardiac, renal, and hepatic function.

Use Cases

• Modeling patient survival and readmission risk based on perioperative clinical characteristics.
• Analyzing correlations between LVAD support and improvements in cardiac function (e.g., ejection fraction).
• Studying the impact of LVAD therapy on organ function (e.g., liver and renal metrics).
• Identifying predictors for the reported 40.74% hospital readmission rate.

Strengths

• Includes longitudinal data with a median follow-up duration of 5.4 months (range 1.1–35.4 months).
• Covers multiple outcome domains: survival, readmission, and changes in cardiac, renal, and hepatic function.
• Provides specific patient cohort details: 27 patients, median age 61 years, 88.9% male.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

Qiuju Ding via figshare.

Collection Method

Single-center, retrospective study.

Time Range

Patient implantations from October 2022 to July 2025.

Freshness

Last updated 2026-04-14 05:28:42; freshness should be verified.

Geography

null